74 related articles for article (PubMed ID: 18358703)
1. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
Tostmann A; Boeree MJ; Peters WH; Roelofs HM; Aarnoutse RE; van der Ven AJ; Dekhuijzen PN
Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703
[TBL] [Abstract][Full Text] [Related]
2. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.
Zhou L; Song Y; Zhao J; Qin H; Zhang G; Zhou Y; Wu X
Pharm Biol; 2016; 54(6):931-7. PubMed ID: 26987268
[TBL] [Abstract][Full Text] [Related]
3. Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen.
Perumal R; Arodola-Oladoyinbo O; Naidoo A; Kawuma AN; Naidoo K; Gengiah TN; Chirehwa M; Padayatchi N; Denti P
Int J Tuberc Lung Dis; 2022 Aug; 26(8):766-774. PubMed ID: 35898135
[No Abstract] [Full Text] [Related]
4. Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug.
Hussain Z; Zhu J; Ma X
Drug Metab Dispos; 2021 Aug; 49(8):679-682. PubMed ID: 34074731
[TBL] [Abstract][Full Text] [Related]
5. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals.
Eminzade S; Uraz F; Izzettin FV
Nutr Metab (Lond); 2008 Jul; 5():18. PubMed ID: 18601745
[TBL] [Abstract][Full Text] [Related]
6. Role of CYP3A in isoniazid metabolism in vivo.
Liu K; Li F; Lu J; Gao Z; Klaassen CD; Ma X
Drug Metab Pharmacokinet; 2014; 29(2):219-22. PubMed ID: 24172716
[TBL] [Abstract][Full Text] [Related]
7. Assessing Polymorphic Purity of Rifampicin in Double and Triple-Drug Fixed-Dose Combination Products.
Antonio M; Raffaghelli M; Maggio RM
J Pharm Sci; 2024 Apr; 113(4):930-936. PubMed ID: 37783271
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine.
Abouzid M; Kosicka-Noworzyń K; Karaźniewicz-Łada M; Rao P; Modi N; Xie YL; Heysell SK; Główka A; Kagan L
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257250
[TBL] [Abstract][Full Text] [Related]
9. Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes.
Lee KK; Boelsterli UA
Redox Biol; 2014; 2():599-609. PubMed ID: 25460728
[TBL] [Abstract][Full Text] [Related]
10. Response to Modified Antitubercular Drug Regime and Antiretroviral Therapy in a Case of HIV Infection with Disseminated Tuberculosis with Isoniazid Induced Toxic Epidermal Necrolysis.
Swami A; Gupta B; Bhattacharjee P
Case Rep Infect Dis; 2012; 2012():626709. PubMed ID: 23259095
[TBL] [Abstract][Full Text] [Related]
11. Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a
Zhao H; Si ZH; Li MH; Jiang L; Fu YH; Xing YX; Hong W; Ruan LY; Li PM; Wang JS
Toxicol Res (Camb); 2017 Jan; 6(1):17-29. PubMed ID: 30090474
[TBL] [Abstract][Full Text] [Related]
12. Investigating the CYP2E1 Potential Role in the Mechanisms Behind INH/LPS-Induced Hepatotoxicity.
Hassan HM; Yousef BA; Guo H; Xiaoxin L; Zhang L; Jiang Z
Front Pharmacol; 2018; 9():198. PubMed ID: 29563874
[TBL] [Abstract][Full Text] [Related]
13. Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study.
Zentner I; Back HM; Kagan L; Subbian S; Nagajyothi J; Srivastava S; Pasipanodya J; Gumbo T; Bisson GP; Vinnard C
Front Pharmacol; 2020; 11():1103. PubMed ID: 32848735
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model.
Singh M; Sasi P; Gupta VH; Rai G; Amarapurkar DN; Wangikar PP
Hum Exp Toxicol; 2012 Aug; 31(8):788-97. PubMed ID: 22318308
[TBL] [Abstract][Full Text] [Related]
15. Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells.
Nicod L; Viollon C; Regnier A; Jacqueson A; Richert L
Hum Exp Toxicol; 1997 Jan; 16(1):28-34. PubMed ID: 9023573
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids of
Omokhua-Uyi AG; Madikizela B; Aro AO; Abdalla MA; Van Staden J; McGaw LJ
S Afr J Bot; 2023 Jul; 158():158-165. PubMed ID: 37206481
[TBL] [Abstract][Full Text] [Related]
17. A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation.
Rampedi PN; Ogunrombi MO; Wesley-Smith J; Adeleke OA
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678693
[TBL] [Abstract][Full Text] [Related]
18. Host Bioenergetic Parameters Reveal Cytotoxicity of Antituberculosis Drugs Undetected Using Conventional Viability Assays.
Cumming BM; Baig Z; Addicott KW; Chen D; Steyn AJC
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0093221. PubMed ID: 34339269
[TBL] [Abstract][Full Text] [Related]
19. Toxicoproteomic Profiling of
Brewer CT; Kodali K; Wu J; Shaw TI; Peng J; Chen T
Cells; 2020 Jul; 9(7):. PubMed ID: 32660103
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
